Citizens JMP Maintains Microbot Medical With Buy Rating, Adjusts Price Target
Citizens JMP analyst Daniel Stauder has maintained a 'Buy' rating on Microbot Medical (MBOT) while lowering the price target from $2.50 to $2.00.
Stocks · News reference
Filed: 2026-11-16 AccNo: 0001493152-26-052054 Size: 267 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Citizens JMP analyst Daniel Stauder has maintained a 'Buy' rating on Microbot Medical (MBOT) while lowering the price target from $2.50 to $2.00.
U.S. stocks fell Monday as tech slid and manufacturing sentiment weakened; oil, gold and silver also declined, while TELUS and H World surged.
U.S. stocks fell, led by a 1.1% Nasdaq drop; tech slid while staples rose. Tyson beat estimates, and small-cap movers saw sharp gains and losses.
Microbot Medical Inc. announced its financial results for the third quarter of 2026, reporting revenue of $72,000.
Microbot Medical Inc. announced that the Canadian Intellectual Property Office (CIPO) has issued a patent for an adaptor designed to couple surgical tools to its robotic surgical system.